Investigation of Appropriate Cultivation Approach for Capsular Polysaccharide Production by Streptococcus pneumoniae Serotype 19F

Mohsen Jalali¹ and Shirin Tarahomjoo^2,

¹Department of Chemical Engineering, North Branch, Azad University of Tehran, Tehran, Iran

²Division of Genomics and Genetic Engineering, Department of Biotechnology and Central Laboratory, Razi Vaccine and Serum Research Institute, Karaj, Iran

Cite this paper:
Mohsen Jalali and Shirin Tarahomjoo. Investigation of Appropriate Cultivation Approach for Capsular Polysaccharide Production by Streptococcus pneumoniae Serotype 19F. American Journal of Microbiological Research. 2015; 3(6):197-200. doi: 10.12691/ajmr-3-6-4

Abstract

With the aim of determining an appropriate cultivation approach for the capsular polysaccharide production by Streptococcus pneumoniae serotype 19F, the influence of environmental and culture medium conditions on the pneumococcal culture was investigated. Using 5% CO₂ atmosphere instead of using an aeration limited environment enhanced the capsule production 3.5 fold. Buffering the cultivation medium prevented the culture pH drop to the acidic condition and increased the capsule production almost 5 fold. Utilizing casamino acid as the nitrogen source of the culture medium instead of soytone provided 1.3 fold increase in the capsule production. Glucose, sorbitol, lactose and sucrose were investigated as carbon sources of the culture medium. Regarding costs of these sugars and their effects on the capsule production, lactose was the best carbon source. Our results demonstrated that buffering the cultivation medium had the most profound effect on the serotype 19F capsule production. The capsule was produced at 1.706 mg/ml in the buffered medium. Applying this culture method allows the cost effective production of the serotype 19F pneumococcal capsule for inclusion in pneumococcal vaccines.

Keywords:
capsular polysaccharide cultivation pneumococcal conjugate vaccines serotype 19F streptococcus pneumoniae

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Mook-Kanamori, B. B., Geldhoff, M., van der Poll, T. and van de Beek, D, “Pathogenesis and pathophysiology of pneumococcal meningitis,” Clin Microbiol Rev, 24 (3), 557-591, Jul. 2011.
[2]	WHO, “Pneumococcal vaccines, WHO position paper,” Wkly Epidemiol Rec, 87 (14), 129-144, Apr. 2012.
[3]	Mukherjee, S., Das, P. and Sen, R, “Towards commercial production of microbial surfactants,” Trends Biotechnol, 24 (11), 509-515, Sep. 2006.
[4]	Kapoor, M., Nair, L. M., Kuhad, R. C, “Cost effective xylynase production from free and immobilized Bacillus pumilus strain MK001 and its application in saccharification of Prosopis juliflora,” Biochem Eng J, 38 (1), 88-97, Jan. 2008.
[5]	Hoskins, J., Alborn, W. E., Arnold, J. et al, “Genome of the bacterium Streptococcus pneumoniae strain R6,” J Bacteriol, 183 (19), 5709-5717, Oct. 2001.
[6]	Härtel, T., Klein, M., Koedel U. et al, “Impact of glutamine transporters on pneumococcal fitness under infection-related conditions,” Infect Immun, 791(), 44-58, Jan. 2011.
[7]	Kerr, A. R., Adrian, P. V., Estevão, S. et al, “The Ami-AliA/AliB permease of Streptococcus pneumoniae is involved in nasopharyngeal colonization but not in invasive disease,” Infect Immun, 72 (7), 3902-3906, Jul. 2004.
[8]	Kloosterman, T. G., Hendriksen, W. T., Bijlsma J. J. et al, “Regulation of glutamine and glutamate metabolism by GlnR and GlnA in Streptococcus pneumoniae,” J Biol Chem, 281 (35), 25097-25109, Sep. 2006.
[9]	Goncalves, V. M., Zangirolami, T. C., Giordano, R. L. C. et al, “Optimization of medium and cultivation conditions for capsular polysaccharide production by Streptococcus pneumoniae serotype 23F,” Appl Microbiol Biotechnol, 59 (6), 713-717, Sep. 2002.
[10]	Leal, M. M., Pereira, D. S. G., Jessouroun, E. et al, “Investigation of cultivation conditions for capsular polysaccharide production by Streptococcus pneumoniae serotype 14,” Elec J Biotechnol, 14 (5), 1-7, 2011.
[11]	Johnson, H. L., Deloria-Knoll, M., Levin, R. S. et al, “Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: the pneumococcal global serotype project,” PLoS Med, 7 (10), e1000348, Oct. 2010.
[12]	Morona, J. K., Miller, D. C., Morona, R. and Paton, J. C, “The effect that mutations in the conserved capsular biosynthesis genes cpsA, cpsB and cpsD have on virulence of Streptococcus pneumoniae,” J Infect Dis, 189 (10), 1905-1913, May 2004.
[13]	Hathaway, L. J., Battig, P. and Muhlemann, K, “In vitro expression of the first capsule gene of Streptococcus pneumoniae, cpsA, is associated with serotype specific colonization prevalence and invasiveness,” Microbiol, 153(8), 2465-2471, Aug. 2007.
[14]	Carvalho, S. M., kuipers, o. P. and Neves, A. R, “Environmental and nutritional factors that affect growth and metabolism of the pneumococcal serotype 2 strain D39 and its nonencapsulated derivative strain R6,” PLos ONE, 8(3), 1-15, March 2013.
[15]	Liberman, C., Takagi, M., Cabrera-Crespo, J. et al, “Pneumococcal whole cell vaccine: optimization of cell growth of unencapsulated Streptococcus pneumoniae in bioreactor using animal-free medium,” J Ind Microbiol Biotechnol, 35(11), 1441-1445, Aug. 2008.
[16]	Biddosi, A., Mulas, L., Decorosi, F. et al, “A functional genomics approach to establish the complement of carbohydrate transporters in Streptococcus pneumoniae,” PLos ONE, 7(3), 1-24, March 2012.